Return to Results

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer

new search

Trial Conditions
  • Breast Cancer
What is the purpose of this trial?

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that of tamoxifen in preventing breast cancer in postmenopausal women.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
35 and older

Gender:
Female

Eligibility

DISEASE CHARACTERISTICS:

- Postmenopausal women at increased risk for developing invasive breast cancer, who
meet one of the following criteria:

- At least 12 months since spontaneous menstrual bleeding

- Prior documented hysterectomy and bilateral salpingo-oophorectomy

- At least 55 years of age with prior hysterectomy with or without oophorectomy

- Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of
ovaries unknown with documented follicle-stimulating hormone level demonstrating
elevation in postmenopausal range

- Histologically confirmed lobular carcinoma in situ treated by local excision only OR
a minimum projected 5 year probability of invasive breast cancer of at least 1.66%,
using Breast Cancer Risk Assessment Profile

- No clinical evidence of malignancy on physical exam within the past 180 days

- No evidence of suspicious or malignant disease on bilateral mammogram within the past
year

- No bilateral or unilateral prophylactic mastectomy

- No prior invasive breast cancer or intraductal carcinoma in situ

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age:

- 35 and over

Sex:

- Female

Menopausal status:

- See Disease Characteristics

Performance status:

- No restricted normal activity for a significant portion of each day

Life expectancy:

- At least 10 years

Hematopoietic:

- Granulocyte count at least 1,500/mm^3

- Complete blood count and differential normal

- Platelet count normal

Hepatic:

- SGOT or SGPT normal

- Bilirubin normal

- Alkaline phosphatase normal

Renal:

- Creatinine normal

Cardiovascular:

- No cerebral vascular accident, transient ischemic attack, atrial fibrillation, or
uncontrolled hypertension

- No deep vein thrombosis

Pulmonary:

- No pulmonary embolus

Other:

- No other prior malignancy within the past 5 years except basal cell or squamous cell
skin cancer or carcinoma in situ of the cervix

- No concurrent nonmalignant disease that would preclude administration of tamoxifen or
raloxifene

- No clinical depression, psychiatric condition, or addictive disorder

- No uncontrolled diabetes

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- Not specified

Endocrine therapy:

- At least 3 months since prior estrogen or progesterone replacement therapy, oral
contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin
inhibitors, or antiandrogens

- At least 3 months since prior tamoxifen, raloxifene, or other selective
estrogen-receptor modulators of less than 3 months duration

- Concurrent Estring allowed

Radiotherapy:

- No prior breast radiotherapy

Surgery:

- See Disease Characteristics

Other:

- No prior systemic adjuvant therapy for breast cancer

- No other participation in a cancer prevention or osteoporosis prevention study
involving pharmacologic intervention(s)

- NSABP-P-1 patients who received placebo are eligible

- No concurrent warfarin or cholestyramine

- Concurrent calcitonin or nonhormonal medication (e.g., cholecalciferol, fluoride, or
bisphosphonates) allowed

Gender: Female
Steward Physician(s)
  • Norman Wolmark, MD
Facilities
  • Saint Anne's Hospital - Completed
  • Norwood Hospital - Completed
Trial Interventions
Drug
  • Raloxifene
  • Tamoxifen
Physician Researcher

Investigator Name:

  • Norman Wolmark, MD

Other Information

Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Phase: Phase 3
Trial ID: NCT00003906
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Share This Page Print This Page

Subscribe to Believe

Our electronic health news
Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions